1. Fate of the abstracts presented at three Spanish clinical pharmacology congresses and reasons for unpublished research

   • E. Montané
   • X. Vidal

   Special Article 06 January 2007 Pages: 103 - 111

   

2. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers

   • S. Efrati
   • M. Averbukh
   • A. Golik

   Clinical Trial 03 January 2007 Pages: 113 - 121

   

3. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension

   • Angelo Tremblay
   • Jean-Philippe Chaput
   • Jean-Pierre Després

   Clinical Trials 03 January 2007 Pages: 123 - 134

   

4. The effect of MK-0524, a prostaglandin D₂ receptor antagonist, on prostaglandin D₂-induced nasal airway obstruction in healthy volunteers

   • A. Van Hecken
   • M. Depré
   • J. N. de Hoon

   Pharmacodynamics 03 January 2007 Pages: 135 - 141

   

5. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

   • Tsukasa Uno
   • Takenori Niioka
   • Tomonori Tateishi

   Pharmacogenetics 04 January 2007 Pages: 143 - 149

   

6. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

   • Paul L. M. van Giersbergen
   • Jasper Dingemanse

   Pharmacokinetics and Disposition 25 April 2006 Pages: 151 - 158

   

7. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl

   • Robert Z. Harris
   • Margaret Salfi
   • Desmond Padhi

   Pharmacokinetics and Disposition 08 May 2006 Pages: 159 - 163

   

8. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases

   • Ying Hong
   • Peter J. Shaw
   • Andrew J. McLachlan

   Pharmacokinetics and Disposition 19 December 2006 Pages: 165 - 172

   

9. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers

   • Annika Allqvist
   • Jun Miura
   • Rajaa A. Mirghani

   Pharmacokinetics and Disposition 03 January 2007 Pages: 173 - 179

   

10. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients

    • Maurits E. L. Arbouw
    • Kris L. L. Movig
    • Toine C. G. Egberts

    Pharmacoepidemiology and Prescription 03 January 2007 Pages: 181 - 187

    

11. Medication administered to children from 0 to 7.5 years in the Avon Longitudinal Study of Parents and Children (ALSPAC)

    • J. Headley
    • K. Northstone

    Pharmacoepidemiology and Prescription Open access 03 January 2007 Pages: 189 - 195

12. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003

    • Paola Deambrosis
    • Cristina Saramin
    • Alessandro Chinellato

    Pharmacoepidemiology and Prescription 03 January 2007 Pages: 197 - 203

    

13. Incorrect use of orlistat and sibutramine in clinical practice

    • Anna Dahlin
    • Björn Beermann

    Pharmacoepidemiology and Prescription 05 January 2007 Pages: 205 - 209

14. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes

    • Yuji Mano
    • Takashi Usui
    • Hidetaka Kamimura

    Short Communication 03 January 2007 Pages: 211 - 216

    

15. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia

    • Kosuke Doki
    • Masato Homma
    • Yukinao Kohda

    Erratum 15 December 2006 Pages: 217 - 218

16. CPT 2008, The IXth World Conference on Clinical Pharmacology and Therapeutics

    Announcement 03 January 2007 Pages: 219 - 219